Lead Sponsor

Merck Sharp & Dohme LLC

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•Has virologically confirmed COVID-19 requiring hospital admission.
•Has respiratory symptoms including cough and dyspnea
•Requires supplemental oxygen therapy
•Male participant is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) (example, 5 terminal half-lives after the last dose of study intervention)
•Female participant is not a woman of childbearing potential (WOCBP) or is a WOCBP who is abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) (example, 5 terminal half-lives after the last dose of study intervention)

•Has pre-existing medical conditions of any nature which are immediately pre-terminal such as death or limitation of life-sustaining therapy is expected to be imminent
•Requires or is expected to require invasive mechanical ventilation
•Requires or is expected to require noninvasive mechanical ventilation
•Has any issue which would prohibit them from effective use of the frespaciguat inhaler
•Hypoxemia which is explained by any condition other than COVID-19, example, preexisting cardiac or pulmonary disease
•Has severe hepatic impairment (meets Child-Pugh Class C criteria)
•Has severe renal impairment and/or requirement for renal dialysis

Related studies

NCT05117125 · Pneumonia, Ventilator-Associated

NCT06834971 · Ventilator-Associated Pneumonia (VAP)

NCT06501118 · Respiratory Failure, Acute Hypoxemic Respiratory Failure, and more

NCT06966310 · Community-acquired Pneumonia

NCT00001352 · Cryptococcal Infection, Cryptococcal Pneumonia, and more

Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)